- According to a WSJ report, the FDA’s decision to authorize the Moderna COVID-19 vaccine for people under the age of 18 has been delayed.
- The delay comes as concerns rise on the jab due to rare cases of heart inflammation in young people
- Last week, three Nordic countries, Denmark, Finland and Sweden, banned the use of the vaccine in young people over concerns about inflammation of the heart.
- The FDA publicly stood by its authorization of the Modern jab earlier this week
- A recent study found that a person is more likely to develop heart inflammation due to covid than the vaccine
The US Food and Drug Administration’ (FDA) is delaying its decision whether to authorize Moderna’s COVID-19 vaccine for teens due to concerns the jab may cause rare heart inflammation.
NS wall street journal (WSJ) reports that the decision which was expected to be made so far has been pushed back by a few weeks.
According to the newspaper, the FDA will be looking at any possible links Moderna has to the inflammation of the heart, known as myocarditis, specifically compared to the Pfizer-BioNtech vaccine.
Last week, three Nordic countries, Denmark, Finland and Sweden, banned the use of the vaccine for youth because of concerns about heart inflammation.
Fourth, Norway also advised young adults and adolescents to choose the Pfizer vaccine over the modern shot.
The FDA publicly defended the Moderna vaccine earlier this week, and concerns over heart inflammation in young people have long been warned by US health officials.
An FDA decision on whether the Moderna COVID-19 vaccine will receive authorization for people under the age of 18 comes amid concerns over the vaccine causing heartburn in young people, according to a report. (file image)
Use of the Moderna COVID-19 vaccine (pictured) has been banned in Denmark, Finland and Sweden after an increased risk of heart inflammation was discovered in young people receiving the jab. Norway has also recommended young people to opt for the Pfizer vaccine instead.
Currently, the Moderna COVID-19 vaccine is available to all Americans age 18 or older.
According to the Centers for Disease Control and Prevention (CDC), it is the second most commonly used vaccine in the US, having been administered more than 153 million times.
It is a two-shot, mRNA-based, vaccine similar to the Pfizer-BioNTech jab, although the Pfizer shot is already authorized in all Americans age 12 and older.
Moderna is competing to get its shot at the same level of authority as its counterpart, although recent concerns emerging in Europe have pushed back the decision.
The Nordic countries decided last week to halt the use of the vaccine among young people.
The Finnish Institute for Health and Welfare said officials would not give the vaccine to men under the age of 30, and they would be offered the Pfizer-BioNTech vaccination instead.
In Sweden, the Modern jab will no longer be available to anyone born after 1990 or aged 30 and under.
Denmark has restricted access to the vaccine to anyone under the age of 18.
Norway has not acted as harshly as its neighbors, with health officials urging people under the age of 30 to opt for the Pfizer vaccine instead.
All four countries based their decision on an unpublished study with the Public Health Agency of Sweden that found an increased risk of myocarditis and pericarditis among young people who had received the shot.
Moderna’s chief medical officer, Dr Paul Burton, told the WSJ that his company has asked Swedish authorities to look into the data but has not yet received it.
Moderna CEO Stephan Bansel told Newswire that the decisions of the Nordic countries are a result of their being too conservative.
“Some countries want to be ultra conservative, that’s certainly their prerogative, but with the data I’ve seen, I can feel comfortable with any young male in my family who is getting vaccinated,” he said. .
The Cambridge, Massachusetts-based company did not respond to a request from DailyMail.com for comment on the matter.
Myocarditis and pericarditis, both types of heart inflammation, are side effects of Covid vaccines, and the Centers for Disease Control and Prevention (CDC) also gives a warning that the condition may develop in young men after vaccination.
Inflammation of the heart is also a symptom of many viral infections, such as COVID-19, however, and the likelihood of developing inflammation after infection is much higher than after vaccination.
A recent study by Kaiser Permanente Southern California found that about seven out of every million people who get the two-shot COVID-19 vaccine will develop myocarditis.
A recent study by the KPSC found that people who received the Covid vaccine were seven times more likely to develop heartburn after the second dose of the jab. However, people who have not been vaccinated have a significantly higher chance of developing myocarditis.
The same study found that 47.5 out of every one million Covid patients experience heart inflammation.
While myocarditis often gets better on its own, it can be dangerous.
Inflammation of the heart can often cause fatigue, shortness of breath and chest pain for patients.
People with an inflamed heart have a higher risk of heart failure, heart attack, and stroke.
Attempting strenuous physical activity with an inflamed heart can potentially lead to sudden cardiac arrest or even death.